Tumor hypoxia imaging

Clinical Cancer Research

Volumn 12, Issue 18, 2006, Pages 5260-5264

  Serganova, Inna ^a   Humm, John ^a   Ling, Clifton ^a   Blasberg, Ronald ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 NITROIMIDAZOLE DERIVATIVE; ERYTHROPOIETIN; FLUORODEOXYGLUCOSE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; GLUCOSE TRANSPORTER; HYPOXIA INDUCIBLE FACTOR 1; MAMMALIAN TARGET OF RAPAMYCIN; OXYGEN; PIMONIDAZOLE; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANAEROBIC GLYCOLYSIS; CANCER RESEARCH; DIAGNOSTIC IMAGING; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; HYDROXYLATION; HYPOXIA; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; ISOTOPE LABELING; METASTASIS; MOLECULAR GENETICS; NOTE; OXYGEN TENSION; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR DIAGNOSIS;

BIOLOGICAL MARKERS; CELL HYPOXIA; FLUORODEOXYGLUCOSE F18; HUMANS; MISONIDAZOLE; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; OXYGEN; POSITRON-EMISSION TOMOGRAPHY;

EID: 33749349542     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0517     Document Type: Note

References (56)

1. 18F]fluoromisonidazole positron emission tomography in head and neck cancer: value of pretherapy fluoromisonidazole uptake in predicting survival. Clin Cancer Res 2006;12:5435-41.
2. 18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245-52.
3. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-7.
4. Ivan M, Kondo K, Yang H, et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464-8.
5. Salceda S, Caro J. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997;272:22642-7.
6. Kaelin WG, Jr. The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun 2005;338:627-38.
7. Semenza GL. Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med 2002;41:79-83.
8. An WG, Kanekal M, Simon MC, et al. Stabilization of wild-type p53 by hypoxia-inducible factor 1α. Nature 1998;392:405-8.
9. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev 2000;14:34-44.
10. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-5.
11. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000;88:1474-80.
12. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999;24:68-72.
13. Semenza GL, Jiang BH, Leung SW, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996;271:32529-37.
14. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
15. Osthus RC, Shim H, Kim S, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000;275:21797-800.
16. Flier JS, Mueckler MM, Usher P, et al. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987;235:1492-5.
17. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15.
18. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-3.
19. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31-9.
20. Nordsmark M, Loncaster J, Aquino-Parsons C, et al. Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother Oncol 2003;67:35-44.
21. Koch CJ, Evans SM. Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. Adv Exp Med Biol 2003;510:285-92.
22. Evans SM, Judy KD, Dunphy I, et al. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 2004;64:1886-92.
23. Bachtiary B, Schindl M, Potter R, et al. Overexpression of hypoxia-inducible factor 1α indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 2003;9:2234-40.
24. Oliver RJ, Woodwards RT, Sloan P, et al. Prognostic value of facultative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection: results of EORTC Translational Research Fund studies. Eur J Cancer 2004;40:503-7.
25. Cooper R, Sarioglu S, Sokmen S, et al. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer 2003;89:870-6.
26. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001;61:7992-8.
27. Loncaster JA, Harris AL, Davidson SE, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001;61:6394-9.
28. Colpaert CG, Vermeulen PB, Fox SB, et al. The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res Treat 2003;81:137-47.
29. Brun NC, Moen A, Borch K, et al. Near-infrared monitoring of cerebral tissue oxygen saturation and blood volume in newborn piglets. Am J Physiol 1997;273:H682-6.
30. Elas M, Williams BB, Parasca A, et al. Quantitative tumor oxymetric images from 4D electron paramagnetic resonance imaging (EPRI): methodology and comparison with blood oxygen level-dependent (BOLD) MRI. Magn Reson Med 2003;49:682-91.
31. Krishna MC, Subramanian S, Kuppusamy P, et al. Magnetic resonance imaging for in vivo assessment of tissue oxygen concentration. Semin Radiat Oncol 2001;11:58-69.
32. Hennig J, Speck O, Koch MA, et al. Functional magnetic resonance imaging: a review of methodological aspects and clinical applications. J Magn Reson Imaging 2003;18:1-15.
33. Gillies RJ, Raghunand N, Karczmar GS, et al. MRI of the tumor microenvironment. J Magn Reson Imaging 2002;16:430-50.
34. Lewis JS, Welch MJ. PET imaging of hypoxia. Q J Nucl Med 2001;45:183-8.
35. 2 inhalation and positron emission tomography, theory, error analysis, and application in humans. Circulation 1996;94:792-807.
36. Gupta AK, Hutchinson PJ, Fryer T, et al. Measurement of brain tissue oxygenation performed using positron emission tomography scanning to validate a novel monitoring method. J Neurosurg 2002;96:263-8.
37. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417-28.
38. Chapman JD, Baer K, Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res 1983;43:1523-8.
39. Lehtio K, Eskola O, Viljanen T, et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;59:971-82.
40. 18F]EF1. J Nucl Med 2000;41:327-36.
41. Urtasun RC, Parliament MB, McEwan AJ, et al. Measurement of hypoxia in human tumours by noninvasive spect imaging of iodoazomycin arabinoside. Br J Cancer Suppl 1996;27:3209-12.
42. 123I-IAZA in healthy volunteers. J Nucl Med 2001;42:1418-23.
43. Zanzonico P, O'Donoghue J, Chapman JD, et al. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging 2004;31:117-28.
44. Chapman JD, Schneider RF, Urbain JL, et al. Single-photon emission computed tomography and positron-emission tomography assays for tissue oxygenation. Semin Radiat Oncol 2001;11:47-57.
45. 4-methylthiosemicarbazone): an agent for radiotherapy. Proc Natl Acad Sci U S A 2001;98:1206-11.
46. 4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med 2001;15:499-504.
47. Burgman P, O'Donoghue JA, Lewis JS, et al. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol 2005;32:623-30.
48. Dehdashti F, Grigsby PW, Mintun MA, et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60 Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 2003;55:1233-8.
49. 18F]fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323-9.
50. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999;19:61-77; quiz 150-1.
51. Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689-95.
52. 18F] fluoro-2-deoxy-D-glucose. Acta Oncol 2000;39:629-37.
53. Rajendran JG, Wilson DC, Conrad EU, et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 2003;30:695-704.
54. Gagel B, Reinartz P, Dimartino E, et al. pO(2) Polarography versus positron emission tomography ([(18)F]fluoromisomdazole, [(18)F]-2-fluoro- 2′-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 2004;180:616-22.
55. Dubois L, Landuyt W, Haustermans K, et al. Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisomdazole PET and immunohistochemistry. Br J Cancer 2004;91:1947-54.
56. 2 measurements in murine tumors. Int J Radiat Oncol Biol Phys 2005;62:854-61.